非小细胞肺癌驱动突变基因的研究进展  

Driver mutations in non-small-cell lung cancer

作　　者：刘璐[1] 周彩存[1] 

机构地区：[1]同济大学附属肺科医院肿瘤科,上海200433

出　　处：《同济大学学报（医学版）》2013年第1期116-119,124,共5页Journal of Tongji University(Medical Science)

基　　金：国家自然科学基金(30873023)

摘　　要：肿瘤相关分子标记物的发现,导致靶向治疗药物迅速发展。我们对近期在非小细胞肺癌中发现的可能影响靶向治疗的相关分子标记物,即所谓的驱动突变基因进行综合分析。期待依据肿瘤个体基因情况而决定的靶向治疗,可使患者在一定程度上获得更大治疗收益。The discovery of cancer molecular markers has led to the development of targeted agents. We review current knowledge about molecular markers in non-small-cell lung cancer which may have potential clinical relevance to targeted therapies. The adoption of tailored treatment according to the genetic make-up of individual tumors would involve a paradigm shift, but might lead to substantial therapeutic improvement.

关 键 词：非小细胞 肺肿瘤 驱动突变基因 

分 类 号：R734.2[医药卫生—肿瘤]